Resilience

The Washington Post Follow-up to the original CNN report        Oct. 2, 2014

Since the original CNN interview, Logan has been in contact with Dr. Fauci. "I can't say it's a good idea or bad idea," Fauci told The Post this week. "It's one of those things where you're in a situation where you have no therapy, so you look for things that might be available."

Fauci said National Institutes of Health researchers have tested lamivudine's reaction to Ebola in test tubes. There was no response; but Fauci said researchers will adjust some levels and try it again "to see if there's even slight activity against Ebola."

If there is, he said, NIH would consider going to the trial stage.

It makes sense to consider lamivudine as a potential Ebola treatment: It belongs to a group of drugs known as nucleoside analogs, which interfere with the replication processes of certain viruses, Fauci explained.

See Washington Post report

http://www.washingtonpost.com/news/to-your-health/wp/2014/10/02/a-liberian-doctor-is-using-hiv-drugs-to-treat-ebola-victims-the-nih-is-intrigued/

Update of this Morning's story:

Obama tells global health officials: After Ebola, ‘we have to do better.’Obama tells global health officials: After Ebola, ‘we have to do better.’

WASHINGTON POST
By Juliet Eilperin September 26 at 1:30 PM

WASHINGTON --

President Obama addressed health officials from dozens of countries who had gathered Friday at the White House to determine ways the international community can strengthen defenses against future epidemics, such as the Ebola outbreak now raging in West Africa.

Administration officials had launched a global health security initiative in February to help other nations develop basic disease detection and monitoring systems to contain the spread of deadly illnesses.

New York Times

CDC  releases report on worst and best case estimates for Ebola cases. 

Estimates cover Liberia and Sierra Leone, based on computer modeling. Guinea not included because data  "cannot be reliably modeled."

Best case-model, which assures the dead are buried safely and 70 per cent of the patients are treated in settings that reduce the risk of transmission, suggest the epidemic could almost be ended by Jan. 20.

http://www.nytimes.com/2014/09/24/health/ebola-cases-could-reach-14-million-in-4-months-cdc-estimates.html?emc=edit_na_20140923&nlid=12644555&_r=0

LINK TO THE CDC REPORT TEXT

http://apps.washingtonpost.com/g/page/national/ebola-cases-could-skyrocket-by-2015-says-cdc/1337/

CDC RELEASES ESTIMATES OF EBOLA CASES, COULD REACH 1.4 MILLION
http://www.cdc.gov/mmwr/preview/mmwrhtml/su6303a1.htm?s_cid=su6303a1_w

Washington Post

by Abby Ohlheiser September 23 at 11:45 AM

London based scientists, working with international aid groups, are planning to start the first clinical trials in West Africa for drugs to treat Eboa. The trials could begin in a matter of months.

Wellcome Trust's $5 million initiative will include drugs from Mapp Biopharmaceutical, Sarepta and Tekmira, according to Reuters. Mapp makes zMapp, the experimental cocktail administered to two Americans who contracted the disease in Liberia. Tekmira recently gained the approval of the U.S. Food and Drug Administration to use its TKM-Ebola treatment on confirmed or suspected cases of the disease.

Both drugs are still in the experimental phase; researchers have not yet determined the safety or effectiveness of the treatments.

Text of full story: